WO2004014322A3 - Immunomodulatory compositions, methods of making, and methods of use thereof - Google Patents
Immunomodulatory compositions, methods of making, and methods of use thereof Download PDFInfo
- Publication number
- WO2004014322A3 WO2004014322A3 PCT/US2003/025415 US0325415W WO2004014322A3 WO 2004014322 A3 WO2004014322 A3 WO 2004014322A3 US 0325415 W US0325415 W US 0325415W WO 2004014322 A3 WO2004014322 A3 WO 2004014322A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- immunomodulatory
- making
- immunomodulatory compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002494911A CA2494911A1 (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory compositions, methods of making, and methods of use thereof |
EP03785275A EP1551376A4 (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory compositions, methods of making, and methods of use thereof |
AU2003259827A AU2003259827B2 (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory compositions, methods of making, and methods of use thereof |
NZ538628A NZ538628A (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory compositions, methods of making, and methods of use thereof |
JP2004528123A JP2006505523A (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory composition, method for making and using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40296802P | 2002-08-12 | 2002-08-12 | |
US60/402,968 | 2002-08-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004014322A2 WO2004014322A2 (en) | 2004-02-19 |
WO2004014322A3 true WO2004014322A3 (en) | 2004-07-08 |
Family
ID=31715915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/025415 WO2004014322A2 (en) | 2002-08-12 | 2003-08-12 | Immunomodulatory compositions, methods of making, and methods of use thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US7884083B2 (en) |
EP (1) | EP1551376A4 (en) |
JP (1) | JP2006505523A (en) |
KR (1) | KR20050052467A (en) |
CN (1) | CN100471486C (en) |
AU (1) | AU2003259827B2 (en) |
CA (1) | CA2494911A1 (en) |
NZ (1) | NZ538628A (en) |
SG (1) | SG172476A1 (en) |
WO (1) | WO2004014322A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE45196E1 (en) | 2005-03-04 | 2014-10-14 | Dynavax Technologies Corporation | Compositions comprising structurally stable conjugate molecules |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
EP2423335B1 (en) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP1575977B1 (en) | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
PL1794174T3 (en) * | 2004-09-01 | 2012-11-30 | Dynavax Tech Corp | Methods and compositions for inhibition of innate immune responses and autoimmunity |
WO2006066003A2 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
KR100723251B1 (en) | 2005-03-18 | 2007-05-29 | 전숙영 | A pharmaceutical composition for the treatment of allergic diseases, use thereof, and a method for treatment of allergic diseases |
EP2094849B1 (en) * | 2006-11-09 | 2014-01-08 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
EP2209896B1 (en) | 2007-10-26 | 2017-03-01 | Dynavax Technologies Corporation | Methods and compositions for inhibition of immune responses and autoimmunity |
CA2724418A1 (en) * | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
US20110159023A1 (en) * | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
CN102203588B (en) | 2008-10-31 | 2015-03-18 | 生物梅里埃公司 | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
US8647835B2 (en) | 2008-10-31 | 2014-02-11 | BIO MéRIEUX, INC. | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
CN102272602B (en) * | 2008-10-31 | 2014-03-12 | 生物梅里埃公司 | Methods for isolation and identification of microorganisms |
BRPI0919896A2 (en) * | 2008-10-31 | 2016-02-16 | Bio Merieux Inc | methods for the separation, characterization and / or identification of microorganisms by mass spectroscopy. |
CN102272601B (en) | 2008-10-31 | 2014-09-17 | 生物梅里埃公司 | Methods for separation and characterization of microorganisms using identifier agents |
US10167494B2 (en) | 2008-10-31 | 2019-01-01 | Biomerieux, Inc. | Method for detection, characterization and/or identification of microorganisms in a sealed container |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
NZ593220A (en) | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US8343912B2 (en) | 2008-12-23 | 2013-01-01 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
CA3033133C (en) | 2009-03-25 | 2021-11-09 | The Board Of Regents Of The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US8293537B2 (en) * | 2010-02-10 | 2012-10-23 | Selinfreund Richard H | Systems and methods for hemoglobin analysis |
JP2013523792A (en) * | 2010-04-08 | 2013-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pharmaceutical combination containing a PDE4 inhibitor and an EP4 receptor antagonist |
AU2011259718B2 (en) * | 2010-05-28 | 2016-03-03 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and CpG as sole adjuvant - carrier molecules |
KR101810593B1 (en) | 2010-06-16 | 2017-12-22 | 다이나박스 테크놀로지 코퍼레이션 | Methods of treatment using tlr7 and/or tlr9 inhibitors |
US8415307B1 (en) | 2010-06-23 | 2013-04-09 | Biosource Pharm, Inc. | Antibiotic compositions for the treatment of gram negative infections |
WO2012048333A1 (en) * | 2010-10-08 | 2012-04-12 | R.P. Scherer Technologies, Llc | Oral vaccine fast-dissolving dosage form using starch |
US8735091B2 (en) | 2012-05-17 | 2014-05-27 | Biomerieux, Inc. | Methods for inactivation and extraction of acid-fast bacteria for characterization and/or identification using mass spectrometry |
US10894963B2 (en) | 2013-07-25 | 2021-01-19 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
EP3316874A4 (en) * | 2015-06-30 | 2019-03-06 | The Trustees Of The University Of Pennsylvania | Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions |
JP2018527925A (en) | 2015-08-24 | 2018-09-27 | ビオメリュー・インコーポレイテッド | Method for inactivating and extracting mycobacteria from liquid media for characterization and / or identification using mass spectrometry |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
US20200370033A1 (en) * | 2018-01-03 | 2020-11-26 | Regents Of The University Of Minnesota | Biological assembly including biological component and shield |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6451325B1 (en) * | 1989-05-25 | 2002-09-17 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US6458370B1 (en) * | 1997-12-16 | 2002-10-01 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
US6613751B2 (en) * | 2000-02-23 | 2003-09-02 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US4587329A (en) | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
US5338532A (en) | 1986-08-18 | 1994-08-16 | The Dow Chemical Company | Starburst conjugates |
US6312679B1 (en) | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
PT88550A (en) | 1987-09-21 | 1989-07-31 | Ml Tecnology Ventures Lp | PROCESS FOR THE PREPARATION OF NON-NUCLEOTIDIC LIGACATION REAGENTS FOR NUCLEOTIDIAL PROBES |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
US5709879A (en) * | 1990-06-29 | 1998-01-20 | Chiron Corporation | Vaccine compositions containing liposomes |
JPH09502092A (en) | 1993-09-02 | 1997-03-04 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | Enzymatic nucleic acid containing non-nucleotide |
US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
EP0879284B1 (en) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US5851818A (en) | 1996-05-31 | 1998-12-22 | Sequus Pharmaceuticals, Inc. | Condensed plasmid-liposome complex for transfection |
WO1997046251A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
ATE292980T1 (en) | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
CA2291483C (en) | 1997-06-06 | 2012-09-18 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009413B1 (en) | 1997-09-05 | 2007-02-14 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
US6391336B1 (en) | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
EP0992482A1 (en) * | 1998-10-01 | 2000-04-12 | Kvaerner Process Technology Limited | Process |
EP0990638A1 (en) * | 1998-10-01 | 2000-04-05 | Kvaerner Process Technology Limited | Process |
US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
CA2363141C (en) * | 1999-02-26 | 2010-04-06 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
WO2000075105A1 (en) | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
ATE419869T1 (en) * | 1999-08-19 | 2009-01-15 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE USING IMMUNSTIMULATIVE SEQUENCES AND COMPOSITIONS THEREOF |
DE60036950T2 (en) | 1999-08-27 | 2008-08-07 | Inex Pharmaceuticals Corp., Burnaby | COMPOSITIONS FOR STIMULATING CYTOKIN SECRETION AND INDUCING AN IMMUNE RESPONSE |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
JP2001251541A (en) * | 2000-03-06 | 2001-09-14 | Asahi Optical Co Ltd | Camera provided with liquid crystal display device |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) * | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
EP1409010A4 (en) | 2000-07-03 | 2005-06-29 | Probendo Pty Ltd | Treating endotoxemia and related disorders with probiotics |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
EP2423335B1 (en) * | 2001-06-21 | 2014-05-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same |
CA2473717A1 (en) * | 2002-01-25 | 2003-07-31 | Glaxo Group Limited | Dna dosage forms |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
EP1575977B1 (en) * | 2002-12-23 | 2009-09-09 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
GB0323968D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
CA2600036A1 (en) * | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
EP2094849B1 (en) * | 2006-11-09 | 2014-01-08 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
EP2187961A2 (en) * | 2007-08-21 | 2010-05-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
-
2003
- 2003-08-12 NZ NZ538628A patent/NZ538628A/en unknown
- 2003-08-12 CN CNB038194937A patent/CN100471486C/en not_active Expired - Fee Related
- 2003-08-12 JP JP2004528123A patent/JP2006505523A/en not_active Ceased
- 2003-08-12 KR KR1020057002381A patent/KR20050052467A/en not_active Application Discontinuation
- 2003-08-12 EP EP03785275A patent/EP1551376A4/en not_active Withdrawn
- 2003-08-12 CA CA002494911A patent/CA2494911A1/en not_active Abandoned
- 2003-08-12 WO PCT/US2003/025415 patent/WO2004014322A2/en active Application Filing
- 2003-08-12 SG SG2007010127A patent/SG172476A1/en unknown
- 2003-08-12 US US10/640,172 patent/US7884083B2/en not_active Expired - Fee Related
- 2003-08-12 AU AU2003259827A patent/AU2003259827B2/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451325B1 (en) * | 1989-05-25 | 2002-09-17 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6458370B1 (en) * | 1997-12-16 | 2002-10-01 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
US6613751B2 (en) * | 2000-02-23 | 2003-09-02 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
Non-Patent Citations (6)
Title |
---|
HUNTER S.K. ET AL.: "Biodegradable microspheres containing group B streptococcus vaccine: immune response in mice", AM. J. OBSTET. GYNECOL., vol. 185, November 2001 (2001-11-01), pages 1174 - 1179, XP002976980 * |
O'HAGAN D.T.: "Recent developments in vaccine derlivery systems", CURRENT DRUG TARGETS - INFECTIOUS DISORDERS, vol. 1, 2001, pages 273 - 286, XP002976981 * |
See also references of EP1551376A4 * |
SINGH M. ET AL.: "Cationic microparticles are an effective delivery system for immunie stimulatory CpG DNA", PHARMACEUTICAL RESEARCH, vol. 18, no. 10, October 2001 (2001-10-01), pages 1476 - 1479, XP002976979 * |
SINGH M., O'HAGAN D.T.: "Recent advances in vaccine adjuvants", PHARMACEUTICAL RESEARCH, vol. 19, no. 6, June 2002 (2002-06-01), pages 715 - 728, XP002976978 * |
SINGH M., SRIVASTAVA I.: "Advances in vaccine adjuvants for infectious diseases", CURRENT HIV RESEARCH, vol. 1, 2003, pages 309 - 320, XP002976977 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE45196E1 (en) | 2005-03-04 | 2014-10-14 | Dynavax Technologies Corporation | Compositions comprising structurally stable conjugate molecules |
Also Published As
Publication number | Publication date |
---|---|
EP1551376A4 (en) | 2010-10-06 |
US7884083B2 (en) | 2011-02-08 |
CA2494911A1 (en) | 2004-02-19 |
AU2003259827B2 (en) | 2008-09-04 |
CN1674878A (en) | 2005-09-28 |
US20090017075A1 (en) | 2009-01-15 |
AU2003259827A1 (en) | 2004-02-25 |
WO2004014322A2 (en) | 2004-02-19 |
EP1551376A2 (en) | 2005-07-13 |
NZ538628A (en) | 2008-06-30 |
JP2006505523A (en) | 2006-02-16 |
KR20050052467A (en) | 2005-06-02 |
SG172476A1 (en) | 2011-07-28 |
CN100471486C (en) | 2009-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004014322A3 (en) | Immunomodulatory compositions, methods of making, and methods of use thereof | |
WO2003037860A3 (en) | Purine analogs having hsp90-inhibiting activity | |
WO2004074244A3 (en) | Pyrimidine compounds | |
WO2006034154A3 (en) | Salts of 5-azacytidine | |
WO2003095455A3 (en) | Substituted pyrazolopyrimidines | |
WO2005004818A3 (en) | Heterocyclic compounds and their use as anticancer agents | |
MY134136A (en) | Novel compounds comprising jak3 kinase inhibitors | |
WO2006037024A3 (en) | Salts of decitabine | |
WO2003037271A3 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
WO2007120647A3 (en) | Compositions useful as inhibitors of voltage-gated sodium channels | |
WO2003093269A3 (en) | Substituted pyrazolo-pyrimidine-4-ones | |
WO2006119400A3 (en) | Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-trianzin-6-ones, and their use as fungicides | |
CA2475302A1 (en) | Controlled synthesis of ziprasidone and compositions thereof | |
WO2004106293A3 (en) | Oxazolyl - and thiazolyl - purine based tricyclic compounds. | |
HK1155146A1 (en) | Indene derivatives as pharmaceutical agents | |
WO2003082857A3 (en) | Lansoprazole polymorphs and processes for preparation thereof | |
WO2003057145A3 (en) | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES | |
WO2004093800A3 (en) | Thyronamine derivatives and analogs and methods of use thereof | |
RS98704A (en) | New pharmaceutical compositions containing flibanserin polymorpha | |
WO2005117543A3 (en) | N-sulfonylcarboximidamide apoptosis promoters | |
WO2001098245A3 (en) | Triphenyl compounds as interleukin-4 antagonists | |
WO2004032908A3 (en) | Method of inhibiting angiogenesis | |
WO2002067865A3 (en) | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | |
WO2005055939A3 (en) | Vinca derivatives | |
EP1944027A4 (en) | Pharmaceutical composition for treatment or prevention of nephritis and method for producing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2494911 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003785275 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057002381 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004528123 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038194937 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003259827 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 538628 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057002381 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003785275 Country of ref document: EP |